Lantheus Proposes Board Declassification and Approves New Equity Incentive Plan with 2M Additional Shares
LNTH sits 61% above its 52-week low of $47.25 on elevated volume (1.8× avg).
Summary
Lantheus Holdings, Inc. filed its definitive proxy statement, proposing to declassify its Board of Directors and seeking shareholder approval for an Amended and Restated 2026 Equity Incentive Plan, which would add 2 million shares for issuance.
Key Events · Corporate Governance and Compliance · LNTH
-
Board Declassification Proposal
Shareholders will vote on amending the charter to declassify the Board, phasing in annual director elections by 2029, enhancing accountability. This follows a non-binding shareholder proposal in 2025.
-
New Equity Incentive Plan Proposed
The company proposes adding 2,000,000 shares to the 2026 Equity Incentive Plan. If all authorized shares were issued, this would represent approximately 3.08% potential dilution based on 64,971,604 outstanding shares as of March 6, 2026. The total overhang (outstanding awards + available shares + new shares) would increase from 7.57% to 10.65%.
-
Executive Compensation Details
The filing details 2025 executive compensation, including a $13,346,521 earnout for Dr. Ludger Dinkelborg related to the Life Molecular acquisition. Other named executive officers received an average of 47% of their target bonuses due to underperformance against financial goals.
Analysis · LNTH · Life Sciences
This definitive proxy statement outlines key proposals for the upcoming annual meeting, following a preliminary filing. The proposed declassification of the Board of Directors is a significant governance enhancement, moving towards greater accountability by enabling annual director elections. Concurrently, the company is seeking approval for a substantial increase of 2 million shares for its equity incentive plan, which represents notable potential dilution for existing shareholders. While necessary for attracting and retaining talent in a competitive industry, this level of dilution warrants investor attention. The executive compensation disclosures also reveal a large acquisition-related earnout for a key executive and overall underperformance against financial targets for other named executive officers in 2025, impacting their bonus payouts.
At the time of this filing, LNTH was trading at $76.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $47.25 to $108.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.